ERG245
Product Specifications
Target
Others
Related Pathways
Others
Bioactivity
ERG245 is a BCAT1 inhibitor that promotes oxidative phosphorylation (OXPHOS) in CD8+ T cells by selectively inhibiting the enzymatic activity of BCAT1, thereby increasing the cytotoxic capacity of CD8+ T cells. ERG245, when administered in combination with the anti-PD-1 antibody Pembrolizumab, induces tumor regression in preclinical settings, and it can be used as a research agent within the field of immuno-oncology.
Smiles
BrC1=CC=C(C(C(C2=CC=CC=C2)CCC(O)=O)=O)C=C1
Molecular Formula
C17H15BrO3
Molecular Weight
347.2
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-D195100-25MG 25 mg
dCpdC 4-(3-Pyridyl)-4-oxobutyl Phosphate Ester
Sign In for Pricing
View Details 
ARP49796_P050 100 µL
TMEM106C antibody - middle region (ARP49796_P050)
Sign In for Pricing
View Details